RxDoctor Payments Data

Sanjay Batish, MD

Family Medicine · Leland, NCNPI 1700876901

Payments from drug & device makers

$626in general payments, 2019–2025

Across 11 payments — averaging $56.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eko Health, Inc.$200
  • Dexcom, Inc.$147
  • Amgen$132
  • Novo Nordisk$61
  • Baxter Healthcare$39
  • Exact Sciences$20
  • plus $27 from 2 others

What the payments were for

  • Speaking & faculty fees$20032%
  • Food & beverage$42668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eko Health, Inc.1$200
Dexcom, Inc.2$147
Amgen(2 entities)2$132
Novo Nordisk2$61
Baxter Healthcare1$39
Exact Sciences1$20
GSK1$16
Boston Scientific1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$626 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$160,196
Medicare patients
284
Services billed
3,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$106,694
TrulicityDulaglutide75$81,599
EliquisApixaban60$43,753
JanuviaSitagliptin Phosphate30$34,888
XareltoRivaroxaban26$31,846
FarxigaDapagliflozin Propanediol30$28,132
Lurasidone Hcl26$26,857
JardianceEmpagliflozin20$18,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,913
ArexvyRsvpref3 Antigen/As01e/Pf44$13,828
Breo ElliptaFluticasone/Vilanterol22$8,230
Aripiprazole19$8,054
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,375
Atorvastatin Calcium368$4,200
Albuterol Sulfate HfaAlbuterol Sulfate106$3,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$106,69482 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$16$43,345120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Leland

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →